Man Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Man Group’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,104	Closed	-$218K	–	2027
2020 Q4	$218K	Buy	+6,104	New	+$105K	﹤0.01%	1719
2018 Q4	–	Sell	-2,811	Closed	-$60K	–	2154
2018 Q3	$60K	Hold	2,811	–	–	﹤0.01%	2059
2018 Q2	$120K	Buy	2,811 +547	+24%	+$25.1K	﹤0.01%	2064
2018 Q1	$148K	Buy	+2,264	New	+$160K	﹤0.01%	1943

Other funds holding LUMO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's LUMO Position: Q1 2021 in Review

Man Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2021, closing a stake of 6,104 shares — an estimated $218K sold.

Man Group first reported a position in LUMO in Q1 2018 and held it in 4 quarters. The position peaked at $218K in Q4 2020. 41 funds tracked by Wall St. Rank hold LUMO as of Q1 2021.

Man Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Man Group sold 6,104 Lumos Pharma, Inc. Common Stock shares in Q1 2021, an estimated $218K.
Man Group first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Man Group's Lumos Pharma, Inc. Common Stock position peaked at $218K in Q4 2020.
41 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2021.

Based on Man Group's 13F filing for Q1 2021, filed 17 May 2021.